Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

Thumbnail

West Virginia achieves 1st-ever heart transplant

A 61-year-old patient at the West Virginia University Heart and Vascular Institute is the first in the state to receive a successful heart transplant, WVU reported Nov. 10.

Thumbnail

Multiarterial CABG deemed superior to single-arterial approach

Multiarterial CABG was linked to lower rates of long-term mortality, reintervention and MI than single-arterial CABG in a recent study of heart patients, suggesting the multiarterial approach is underused in contemporary practice.

Thumbnail

Destination Question: Should All STEMI Patients Recover in the ICU?

Two studies reach conflicting conclusions while underscoring the need for best practice guidelines to fill the current vacuum.

Thumbnail

1st US center performs PCI using Impella 5.5

Hackensack University Medical Center is the first practice in the U.S. to successfully perform heart surgeries using Abiomed’s Impella 5.5 LVAD.

Thumbnail

Frailty screening in CABG patients cuts costs, but there’s a catch

Frailty assessments are a good value for their money in older patients considering CABG, according to a study published in the Canadian Journal of Cardiology, but a limited geriatric consultation workforce could curb that benefit in real-life practice.

Thumbnail

UFR-guided hydration minimizes contrast-induced complications in CKD patients

Urine flow rate-guided hydration, as opposed to left ventricular end-diastolic pressure-guided hydration, could prevent more complications in CKD patients who are at a high risk for contrast-induced kidney injury.

Thumbnail

Ticagrelor alone reduces bleeding risk after PCI, DAPT

Results from the late-breaking TWILIGHT trial suggest that, among high-risk patients who have undergone PCI and completed three months of dual antiplatelet therapy, it’s safer to continue treatment with ticagrelor alone rather than add aspirin to that cocktail.

Thumbnail

Shorter-duration DAPT looks favorable for patients at a high risk of bleeding after PCI

A shortened, three-month course of dual antiplatelet therapy might be a safer bet than 12-month treatment for patients at a high risk of bleeding after PCI and implantation of a drug-eluting stent.